Nicole LaBrosse - 15 Feb 2022 Form 4 Insider Report for HALOZYME THERAPEUTICS, INC. (HALO)

Role: SVP, Chief Financial Officer
Signature: /s/ James R. Oehler as attorney-in-fact for Nicole LaBrosse
Issuer symbol: HALO
Transactions as of: 15 Feb 2022
Net transactions value: -$14,908
Form type: 4
Filing time: 17 Feb 2022, 17:03:40 UTC
Previous filing: 14 Feb 2022
Next filing: 16 Nov 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HALO	Common Stock	Options Exercise	$0	+1,255	+15%	$0.000000	9,478	15 Feb 2022	Direct
transaction	HALO	Common Stock	Tax liability	$14,908	-433	-4.6%	$34.43	9,045	15 Feb 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HALO	Restricted Stock Units	Options Exercise	$0	-1,255	-25%	$0.000000	3,762	15 Feb 2022	Common Stock	1,255	$0.000000	Direct	F2
transaction	HALO	Option to Purchase Common Stock	Award	$0	+62,315		$0.000000	62,315	16 Feb 2022	Common Stock	62,315	$34.36	Direct	F3
transaction	HALO	Restricted Stock Units	Award	$0	+20,373		$0.000000	20,373	16 Feb 2022	Common Stock	20,373	$0.000000	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported disposition of 433 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2	This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
F3	This option vests one-fourth on such date and then 1/48th monthly thereafter.
F4	This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter.